This product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma cell line, in which the ARPIN gene has been disrupted. The polyclonal nature ensures a heterogeneous allelic spectrum, offering a robust loss-of-function background for studying ARPIN-dependent phenotypes without the clonal bias of monoclonal lines. The gene disruption is achieved through standard CRISPR/Cas9 methodology, resulting in loss of ARPIN protein and enabling study of actin dynamics and motility.
The A-549 cell line is a widely accepted model of human lung adenocarcinoma, exhibiting epithelial characteristics and representing alveolar basal epithelial cells. Established from a patient with lung carcinoma, these cells are a mainstay in respiratory disease research and possess intact signaling cascades relevant to cancer progression and metastasis. Their adherent growth, ease of transfection, and consistent phenotype make them an ideal host for CRISPR/Cas9-mediated genome editing, ensuring reproducible experimental outcomes in migration, invasion, and cytoskeletal studies.
ARPIN is a dedicated inhibitor of the Arp2/3 complex, the principal nucleator of branched actin networks that drive lamellipodia extension and cell migration. By binding directly to Arp2/3 and actin filaments, ARPIN blocks nucleation activity, effectively reducing membrane protrusion and motility. ARPIN function is modulated by upstream signals including Rac1 and Cdc42, which act via the WAVE complex to activate Arp2/3, as well as by PI3K/Akt signaling and mechanical stress. Knockout lifts this inhibition, leading to unchecked Arp2/3-mediated actin polymerization and enhanced lamellipodia formation.
In A-549 lung adenocarcinoma cells, ARPIN knockout promotes a pro-migratory and pro-invasive state, closely mimicking the heightened motility associated with metastatic dissemination. Disinhibition of Arp2/3-driven actin branching in these cells may accelerate matrix remodeling and invasion??processes central to cancer metastasis. Consequently, this model is strategically positioned to investigate the molecular mechanisms of tumor cell motility and to evaluate therapeutic interventions that target the actin cytoskeleton, such as small-molecule inhibitors of the Arp2/3 complex or upstream regulators like Rac1 and Cdc42.
Multiple experimental applications use this polyclonal knockout population. Western blotting and RT-qPCR enable confirmation of ARPIN depletion and monitoring of Arp2/3 complex components, while phospho-specific antibodies assess activation of Rac1, Cdc42, and Akt. Functional assays like Transwell migration and wound healing quantify motility, and phalloidin staining with confocal microscopy visualizes actin network alterations. Co-immunoprecipitation studies can further probe ARPIN-Arp2/3 interactions. These cells are also suitable for drug screening campaigns focusing on cytoskeletal dynamics. For further information or to discuss custom solutions, please contact Ascent Research.
